{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:32:31Z","timestamp":1770424351479,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-024-03901-7","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T16:10:07Z","timestamp":1734538207000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Economic evaluation of adding dapagliflozin to standard care in the treatment of chronic kidney disease: a systematic review"],"prefix":"10.1186","volume":"25","author":[{"given":"Lu","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinglin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"3901_CR1","doi-asserted-by":"publisher","unstructured":"Nava-Vargas MG, Arellano-Arteaga KJ, Cort\u00e9s-Sanabria L, et al. Wcn23-1211 cost-effectiveness analysis of Dapagliflozin for Diabetic kidney disease in Mexico. Kidney Int Rep. 2023;8(3). https:\/\/doi.org\/10.1016\/j.ekir.2023.02.459.","DOI":"10.1016\/j.ekir.2023.02.459"},{"issue":"4","key":"3901_CR2","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1001\/jamainternmed.2022.6817","volume":"183","author":"L Wang","year":"2023","unstructured":"Wang L, Xu X, Zhang M, et al. Prevalence of chronic kidney disease in China: results from the Sixth China Chronic Disease and risk factor surveillance. JAMA Intern Med. 2023;183(4):298\u2013310. https:\/\/doi.org\/10.1001\/jamainternmed.2022.6817.","journal-title":"JAMA Intern Med"},{"issue":"3","key":"3901_CR3","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.1016\/S2214-109X(23)00570-3","volume":"12","author":"AK Bello","year":"2024","unstructured":"Bello AK, Okpechi IG, Levin A, et al. An update on the global disparities in kidney disease burden and care across world countries and regions. Lancet Glob Health. 2024;12(3):e382\u201395. https:\/\/doi.org\/10.1016\/S2214-109X(23)00570-3.","journal-title":"Lancet Glob Health"},{"issue":"1","key":"3901_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"Kovesdy","year":"2022","unstructured":"Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022;12(1):7\u201311. https:\/\/doi.org\/10.1016\/j.kisu.2021.11.003.","journal-title":"Kidney Int Suppl (2011)"},{"issue":"6","key":"3901_CR5","doi-asserted-by":"publisher","first-page":"414","DOI":"10.2471\/BLT.17.206441","volume":"96","author":"VA Luyckx","year":"2018","unstructured":"Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ. 2018;96(6):414\u2013D22. https:\/\/doi.org\/10.2471\/BLT.17.206441.","journal-title":"Bull World Health Organ"},{"key":"3901_CR6","doi-asserted-by":"publisher","first-page":"e074216","DOI":"10.1136\/bmj-2022-074216","volume":"383","author":"TK Chen","year":"2023","unstructured":"Chen TK, Hoenig MP, Nitsch D, et al. Advances in the management of chronic kidney disease. BMJ. 2023;383:e074216. https:\/\/doi.org\/10.1136\/bmj-2022-074216.","journal-title":"BMJ"},{"issue":"8","key":"3901_CR7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrendo.2011.243","volume":"8","author":"E Ferrannini","year":"2012","unstructured":"Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8(8):495\u2013502. https:\/\/doi.org\/10.1038\/nrendo.2011.243.","journal-title":"Nat Rev Endocrinol"},{"key":"3901_CR8","doi-asserted-by":"publisher","unstructured":"Zhang Y, Liao XY, Guo R et al. Clinical Application of Sodium Glucose Transporter 2 Inhibitors in Type 2 Diabetics Mellitus with Chronic Kidney. Chinese General Practice. 2020; 23: 3655\u20133660. https:\/\/doi.org\/10.12114\/j.issn.1007-9572.2020.00.483. Healthwise Knowledgebase. US Pharmacopeia, Rockville. 1998. http:\/\/www.healthwise.org. Accessed 21 Sept 1998.","DOI":"10.12114\/j.issn.1007"},{"key":"3901_CR9","unstructured":"FDA Approves Treatment for Chronic Kidney Disease. 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-treatment-chronic-kidney-disease. Accessed 8 July 2024."},{"key":"3901_CR10","unstructured":"Chinese National Medical Products Administration (NMPA). 2022. https:\/\/www.nmpa.gov.cn\/zwfw\/sdxx\/sdxxyp\/yppjfb\/20220902143708191.html. Accessed 8 July 2024."},{"issue":"2","key":"3901_CR11","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1093\/ndt\/gfz290","volume":"35","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Chertow GM, et al. Rationale and protocol of the Dapagliflozin and Prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transpl. 2020;35(2):274\u201382. https:\/\/doi.org\/10.1093\/ndt\/gfz290.","journal-title":"Nephrol Dial Transpl"},{"issue":"3","key":"3901_CR12","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s11096-022-01532-2","volume":"45","author":"A Rezapour","year":"2023","unstructured":"Rezapour A, Souresrafil A, Shamsaei M, et al. Economic evaluation of ferric carboxymaltose compared with placebo in iron-deficient patients with heart failure: a systematic review. Int J Clin Pharm. 2023;45(3):566\u201376. https:\/\/doi.org\/10.1007\/s11096-022-01532-2.","journal-title":"Int J Clin Pharm"},{"issue":"3","key":"3901_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10549-016-3924-7","volume":"159","author":"V Nerich","year":"2016","unstructured":"Nerich V, Saing S, Gamper EM, et al. Cost-utility analyses of drug therapies in breast cancer: a systematic review. Breast Cancer Res Treat. 2016;159(3):407\u201324. https:\/\/doi.org\/10.1007\/s10549-016-3924-7.","journal-title":"Breast Cancer Res Treat"},{"key":"3901_CR14","doi-asserted-by":"publisher","first-page":"e067975","DOI":"10.1080\/13696998.2021.2014721","volume":"376","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMJ. 2022;376:e067975. https:\/\/doi.org\/10.1080\/13696998.2021.2014721.","journal-title":"BMJ"},{"key":"3901_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1332\/174426410X482999","volume":"6","author":"I Shemilt","year":"2010","unstructured":"Shemilt I, James T, Marcello M. A web-based tool for adjusting costs to a specific target currency and price year. Evid Policy. 2010;6:51\u20139. https:\/\/doi.org\/10.1332\/174426410X482999.","journal-title":"Evid Policy"},{"key":"3901_CR16","doi-asserted-by":"publisher","unstructured":"Buritica MP, D\u00edaz O, Rubio Ponce R. EE370 cost effectiveness evaluation of Dapagliflozin in the treatment of chronic kidney disease in Mexico. Value Health. 2022;25(12). https:\/\/doi.org\/10.1016\/j.jval.2022.09.616.","DOI":"10.1016\/j.jval.2022.09.616"},{"issue":"3","key":"3901_CR17","doi-asserted-by":"publisher","first-page":"e0296067","DOI":"10.1371\/journal.pone.0296067","volume":"19","author":"SK Lim","year":"2024","unstructured":"Lim SK, Lee SWH. Cost-effectiveness analysis of dapagliflozin for people with chronic kidney disease in Malaysia. PLoS ONE. 2024;19(3):e0296067. https:\/\/doi.org\/10.1371\/journal.pone.0296067.","journal-title":"PLoS ONE"},{"issue":"10","key":"3901_CR18","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1111\/dom.15201","volume":"25","author":"BN Nguyen","year":"2023","unstructured":"Nguyen BN, Mital S, Bugden S, et al. Cost-effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes. Diabetes Obes Metab. 2023;25(10):3030\u20139. https:\/\/doi.org\/10.1111\/dom.15201.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"3901_CR19","doi-asserted-by":"publisher","first-page":"S145","DOI":"10.1016\/j.ekir.2021.03.351","volume":"6","author":"P McEwan","year":"2021","unstructured":"McEwan P, Darlington O, Wheeler D, et al. Pos-335 cost-effectiveness of Dapagliflozin as a treatment for chronic kidney disease: a Health-Economic Analysis of Dapa-Ckd. Kidney Int Rep. 2021;6(4):S145\u20136. https:\/\/doi.org\/10.1016\/j.ekir.2021.03.351.","journal-title":"Kidney Int Rep"},{"issue":"12","key":"3901_CR20","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.2215\/CJN.03790322","volume":"17","author":"P McEwan","year":"2022","unstructured":"McEwan P, Darlington O, Miller R, et al. Cost-effectiveness of Dapagliflozin as a treatment for chronic kidney disease: a Health-Economic Analysis of DAPA-CKD. Clin J Am Soc Nephrol. 2022;17(12):1730\u201341. https:\/\/doi.org\/10.2215\/CJN.03790322.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"3901_CR21","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1253\/circj.CJ-22-0086","volume":"86","author":"S Kodera","year":"2022","unstructured":"Kodera S, Morita H, Nishi H, et al. Cost-effectiveness of Dapagliflozin for chronic kidney disease in Japan. Circ J. 2022;86(12):2021\u20138. https:\/\/doi.org\/10.1253\/circj.CJ-22-0086.","journal-title":"Circ J"},{"issue":"13","key":"3901_CR22","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1007\/s11606-021-07311-5","volume":"37","author":"RL Tisdale","year":"2022","unstructured":"Tisdale RL, Cusick MM, Aluri KZ, et al. Cost-effectiveness of Dapagliflozin for non-diabetic chronic kidney disease. J Gen Intern Med. 2022;37(13):3380\u20137. https:\/\/doi.org\/10.1007\/s11606-021-07311-5.","journal-title":"J Gen Intern Med"},{"issue":"3","key":"3901_CR23","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s12325-021-02037-6","volume":"39","author":"K Vareesangthip","year":"2022","unstructured":"Vareesangthip K, Deerochanawong C, Thongsuk D, et al. Cost-utility analysis of Dapagliflozin as an add-on to Standard of Care for patients with chronic kidney disease in Thailand. Adv Ther. 2022;39(3):1279\u201392. https:\/\/doi.org\/10.1007\/s12325-021-02037-6.","journal-title":"Adv Ther"},{"issue":"2","key":"3901_CR24","first-page":"204","volume":"33","author":"L Zhong","year":"2024","unstructured":"Zhong L, Shao H. Cost\u2043utility analysis of dapagliflozin in patients with chronic kidney disease. Chin J New Drugs. 2024;33(2):204\u20138.","journal-title":"Chin J New Drugs"},{"key":"3901_CR25","doi-asserted-by":"publisher","unstructured":"Ordo\u00f1ez J, Hern\u00e1ndez F, Rodr\u00edguez G, et al. EE348 cost-utility analysis of Dapagliflozin in patients with chronic kidney disease in Costa Rica. Value Health. 2022;25(7). https:\/\/doi.org\/10.1016\/j.jval.2022.04.596.","DOI":"10.1016\/j.jval.2022.04.596"},{"key":"3901_CR26","doi-asserted-by":"publisher","unstructured":"Ordo\u00f1ez J, Din\u00e1 E, \u00c1lvarez G, et al. EE31 cost-utility analysis of Dapagliflozin in patients with chronic kidney disease in Dominican Republic. Value Health. 2022;25(7). https:\/\/doi.org\/10.1016\/j.jval.2022.04.283.","DOI":"10.1016\/j.jval.2022.04.283"},{"issue":"7","key":"3901_CR27","doi-asserted-by":"publisher","first-page":"S504","DOI":"10.1016\/j.jval.2022.04.1139","volume":"25","author":"J Ordo\u00f1ez","year":"2022","unstructured":"Ordo\u00f1ez J, Valdes R, Courville K. HTA5 cost-utility analysis of Dapagliflozin in patients with chronic kidney disease in Panama. Value Health. 2022;25(7):S504\u20135. https:\/\/doi.org\/10.1016\/j.jval.2022.04.1139.","journal-title":"Value Health"},{"issue":"2","key":"3901_CR28","doi-asserted-by":"publisher","first-page":"sfae025","DOI":"10.1093\/ckj\/sfae025","volume":"17","author":"P McEwan","year":"2024","unstructured":"McEwan P, Davis JA, Gabb PD, et al. Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial. Clin Kidney J. 2024;17(2):sfae025. https:\/\/doi.org\/10.1093\/ckj\/sfae025.","journal-title":"Clin Kidney J"},{"key":"3901_CR29","unstructured":"Liu GG et al. China guidelines for pharmacoeconomic evaluations (2020 edition). 2020, In: Jin BD, Xu H, editors. Chapter 3 Cost. Beijing; 2020. pp. 167\u2013167."},{"key":"3901_CR30","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2165\/00019053-199813040-00003","volume":"13","author":"A Briggs","year":"1998","unstructured":"Briggs A, Sculpher M. An introduction to Markov Modelling for economic evaluation. PharmacoEconomics. 1998;13:397\u2013409. https:\/\/doi.org\/10.2165\/00019053-199813040-00003.","journal-title":"PharmacoEconomics"},{"key":"3901_CR31","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/ndt\/gfaa234","volume":"35","author":"DC Wheeler","year":"2020","unstructured":"Wheeler DC, Stefansson BV, Batiushin M, et al. The Dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrol Dial Transpl. 2020;35:1700\u201311. https:\/\/doi.org\/10.1093\/ndt\/gfaa234.","journal-title":"Nephrol Dial Transpl"},{"key":"3901_CR32","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1007\/s10157-019-01730-9","volume":"23","author":"S Iimuro","year":"2019","unstructured":"Iimuro S, Kaneko T, Ohashi Y, et al. Analysis of 2897 hospitalization events for patients with chronic kidney disease: results from CKD-JAC study. Clin Exp Nephrol. 2019;23:956\u201368. https:\/\/doi.org\/10.1007\/s10157-019-01730-9.","journal-title":"Clin Exp Nephrol"},{"key":"3901_CR33","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/dom.13217","volume":"20","author":"I Raz","year":"2018","unstructured":"Raz I, Mosenzon O, Bonaca MP, et al. DECLARE-TIMI 58: participants\u2019 baseline characteristics. Diabetes Obes Metab. 2018;20:1102\u201310. https:\/\/doi.org\/10.1111\/dom.13217.","journal-title":"Diabetes Obes Metab"},{"key":"3901_CR34","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1080\/21645515.2019.1578597","volume":"15","author":"I Loperto","year":"2019","unstructured":"Loperto I, Simonetti A, Nardone A, et al. Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence. Hum Vaccines Immunotherapeutics. 2019;15:1035\u201347. https:\/\/doi.org\/10.1080\/21645515.2019.1578597.","journal-title":"Hum Vaccines Immunotherapeutics"},{"issue":"4","key":"3901_CR35","doi-asserted-by":"publisher","first-page":"e0176210","DOI":"10.1371\/journal.pone.0176210","volume":"12","author":"CM Schmucker","year":"2017","unstructured":"Schmucker CM, Blumle A, Schell LK, et al. Systematic review finds that study data not published in full text articles have unclear impact on meta-analyses results in medical research. PLoS ONE. 2017;12(4):e0176210. https:\/\/doi.org\/10.1371\/journal.pone.0176210.","journal-title":"PLoS ONE"},{"key":"3901_CR36","doi-asserted-by":"publisher","first-page":"1254398","DOI":"10.3389\/fendo.2023.1254398","volume":"14","author":"Y Xue","year":"2023","unstructured":"Xue Y, Zou H, Ruan Z, et al. Pharmacoeconomic evaluation of anti-obesity drugs for chronic weight management: a systematic review of literature. Front Endocrinol. 2023;14:1254398. https:\/\/doi.org\/10.3389\/fendo.2023.1254398.","journal-title":"Front Endocrinol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03901-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-024-03901-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03901-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T17:07:53Z","timestamp":1734541673000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-024-03901-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3901"],"URL":"https:\/\/doi.org\/10.1186\/s12882-024-03901-7","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"19 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"This systematic review was limited to published research and did not involve human participants, and as such, human participant protection was not required.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human participant protection"}}],"article-number":"465"}}